Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: A meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Qianqian ^a   Li, Xiaoqing ^b   Li, Wenzhang ^b   Du, Xinmiao ^a   He, Jian Qing ^a   Tao, Chuanmin ^a   Feng, Yulin ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; DRUG EFFECTS; HUMAN; META ANALYSIS; MICROBIOLOGY; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL RATE;

CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MULTIVARIATE ANALYSIS; ODDS RATIO; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL RATE;

EID: 84933073491     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11715     Document Type: Article

References (41)

1. Blanc, D. S., Francioli, P. & Zanetti, G. Molecular Epidemiology of Pseudomonas aeruginosa in the Intensive Care Units-A Review. Open Microbiol J 1, 8-11 doi: 10. 2174/1874285800701010008 (2007).
2. Bassetti, M., Righi, E. & Viscoli, C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem 15, 517-522 (2008).
3. Maschmeyer, G. & Braveny, I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 19, 915-925 (2000).
4. Todeschini, G. et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 3, 99-104 (1998).
5. Gaynes, R., Edwards, J. R. & National Nosocomial Infections Surveillance, S. Overview of nosocomial infections caused by gramnegative bacilli. Clin Infect Dis 41, 848-854 doi: 10. 1086/432803 (2005).
6. Morrow, B. J. et al. Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis 75, 412-416 doi: 10. 1016/j. diagmicrobio. 2012. 12. 012 (2013).
7. Baumgart, A. M., Molinari, M. A. & Silveira, A. C. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14, 433-436 (2010).
8. Gasink, L. B. et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 119 526 e519-525 doi: 10. 1016/j. amjmed. 2005. 11. 029 (2006).
9. King, A., Shannon, K. & Phillips, I. Resistance to imipenem in Pseudomonas aeruginosa. J Antimicrob Chemother 36, 1037-1041 (1995).
10. Acar, J. F. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 24 Suppl 1, S17-18 (1997).
11. Pena, C. et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56, 1265-1272 doi: 10. 1128/aac. 05991-11 (2012).
12. Harbarth, S., Nobre, V. & Pittet, D. Does antibiotic selection impact patient outcome? Clin Infect Dis 44, 87-93 doi: 10. 1086/510075 (2007).
13. Joo, E. J. et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 17, 305-312 doi: 10. 1089/mdr. 2010. 0170 (2011).
14. Hattemer, A. et al. Bacterial and clinical characteristics of health care-and community-acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 57, 3969-3975 doi: 10. 1128/AAC. 02467-12 (2013).
15. Nathwani, D., Raman, G., Sulham, K., Gavaghan, M. & Menon, V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 3, 32 doi: 10. 1186/2047-2994-3-32 (2014).
16. Krcmery, Jr., V. et al. Imipenen-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. Int J Clin Pharmacol Res 16, 43-49 (1996).
17. Cofsky. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 23, 106-108 doi: 10. 1086/502018 (2002).
18. Kang, C. I. et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11, 68-74 doi: 10. 1089/mdr. 2005. 11. 68 (2005).
19. Marra, A. R., Bearman, G. M., Wenzel, R. P. & Edmond, M. B. Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections. BMC Infect Dis 5, 94 doi: 10. 1186/1471-2334-5-94 (2005).
20. Lautenbach, E. et al. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 27, 893-900 doi: 10. 1086/507274 (2006).
21. Eagye, K. J., Kuti, J. L. & Nicolau, D. P. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 30, 746-752 doi: 10. 1086/603527 (2009).
22. Lautenbach, E. et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 31, 47-53 doi: 10. 1086/649021 (2010).
23. Suarez, C. et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int J Infect Dis 14 Suppl 3, e73-78 doi: 10. 1016/j. ijid. 2009. 11. 019 (2010).
24. Babu, K. V. Y. et al. Study of Imipenem Resistant Pseudomonas aeruginosa and Associated Predisposing Risk Factors in a Rural Tertiary Care Hospital. J Pure Appl Microbio 5, 793-800 (2011).
25. Pena, C. et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56, 1265-1272 doi: 10. 1128/AAC. 05991-11 (2012).
26. Tuon, F. F., Gortz, L. W. & Rocha, J. L. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. Braz J Infect Dis 16, 351-356 doi: 10. 1016/j. bjid. 2012. 06. 009 (2012).
27. Lin, K. Y., Lauderdale, T. L., Wang, J. T. & Chang, S. C. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections. J Microbiol Immunol Infect doi: 10. 1016/j. jmii. 2014. 01. 005 (2014).
28. Dantas, R. C., Ferreira, M. L., Gontijo-Filho, P. P. & Ribas, R. M. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol 63, 1679-1687 doi: 10. 1099/jmm. 0. 073262-0 (2014).
29. Kim, Y. J. et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC Infect Dis 14, 161 doi: 10. 1186/1471-2334-14-161 (2014).
30. Lemos, E. V. et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 20, 416-423 doi: 10. 1111/1469-0691. 12363 (2014).
31. Kang, C. I. et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37, 745-751 doi: 10. 1086/377200 (2003).
32. Bjorkman, J. & Andersson, D. I. The cost of antibiotic resistance from a bacterial perspective. Drug Resist Updat 3, 237-245 doi: 10. 1054/drup. 2000. 0147 (2000).
33. Giamarellos-Bourboulis, E. J. et al. Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clin Exp Immunol, 135, 240-246 (2004).
34. El Amin, N. et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113 187-196 doi: 10. 1111/j. 1600-0463. 2005. apm1130306. x (2005).
35. Wirth, F. W. et al. Metallo-beta-lactamase-producing Pseudomonas aeruginosa in two hospitals from southern Brazil. Braz J Infect Dis 13, 170-172 (2009).
36. Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C. & Hughes, J. M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16, 128-140 (1988).
37. Wells, G. A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2014) Available at: http://www. ohri. ca/programs/clinical-epidemiology/oxford. asp. (Accessed: 15th February 2015)
38. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719-748 (1959).
39. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177-188 (1986).
40. Zhang, J. & Yu, K. F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280 1690-1691 (1998).
41. Egger, M., Smith, G. D. & Phillips, A. N. Meta-analysis: principles and procedures. BMJ 315 1533-1537 (1997).